NIM-1324 vs omilancor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: LANCL2 · full Ulcerative Colitis pipeline

NIM-1324

Developed by NImmune Biopharma

Small molecule (oral LANCL2 activator)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

omilancor

Developed by NImmune Biopharma

Phase 2 in Ulcerative ColitisSmall molecule (oral LANCL2 activator)
Partial signal

NCT03861143 · Phase 2 · completed

The study was randomized, triple-blind, placebo-controlled, and included 198 participants, with clinical remission defined using clinical and endoscopic components of the modified Mayo Score. Remission rates favored BT-11 numerically, but statistical significance for the primary endpoint was not reported, so the result remains unclear.

Reported efficacy

Clinical Remission (Week 12): Clinical Remission (Week 12): BT-11 Low-dose (440 mg) 30.3% | BT-11 High-dose (880 mg) 31.8% vs Placebo 22.7% (unclear)

Result source: NCT03861143

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNIM-1324omilancor
Clinical remission (induction)—Not reported31.8% vs 22.7%+9.1 vs placebo880 mg · wk 12 · n 66NCT03861143
1 other result
  • 30.3% vs 22.7% 440 mg · wk 12 · n 66 · Phase 2 · primary NCT03861143
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

NIM-1324
—Not reported
omilancor
31.8% vs 22.7%+9.1 vs placebo880 mg · wk 12 · n 66NCT03861143
1 other result
  • 30.3% vs 22.7% 440 mg · wk 12 · n 66 · Phase 2 · primary NCT03861143

Clinical remission (maintenance)

NIM-1324
—Not reported
omilancor
—Not reported

Clinical response (induction)

NIM-1324
—Not reported
omilancor
—Not reported

Endoscopic improvement (induction)

NIM-1324
—Not reported
omilancor
—Not reported

Corticosteroid-free remission (maintenance)

NIM-1324
—Not reported
omilancor
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NIM-1324: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. NIM-1324: 0 of 4 rows · omilancor: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricomilancor
Dropout rate
10.6%880 mga
NCT03861143 · Phase 2 · monotherapy
show 1 more result
6.1%440 mg
NCT03861143 · Phase 2 · monotherapy
Discontinued due to AEs
—880 mga
NCT03861143 · Phase 2 · monotherapy
show 1 more result
—440 mg
NCT03861143 · Phase 2 · monotherapy
Serious AEs
4.5%880 mga
NCT03861143 · Phase 2 · monotherapy
show 1 more result
3%440 mg
NCT03861143 · Phase 2 · monotherapy
Most frequent reported AEs
880 mga
colitis ulcerative 12.1% (placebo 9.1%)
other 12.1% (placebo 19.7%)
anemia 7.6% (placebo 0%)
NCT03861143 · Phase 2 · monotherapy
show 1 more result
440 mg
colitis ulcerative 15.2% (placebo 9.1%)
other 9.1% (placebo 19.7%)
diarrhea 4.5% (placebo 1.5%)
NCT03861143 · Phase 2 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

omilancor

Clinical Remission 31.8% (n=66) vs 22.7% (n=66) placebo @ 12wk880 mg
responder rate · % of participants
NCT03861143 · Phase 2 · monotherapy
show 1 more result
30.3% (n=66) vs 22.7% (n=66) placebo @ 12wk440 mg
NCT03861143 · Phase 2 · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NIM-1324's landscape · omilancor's landscape